Aethlon Medical, Inc. (OTCQB: AEMD) saw its share volume skyrocket on June 18th with 2,499,437 shares exchanging hands, 8.5 times higher than its three month daily average volume of 293,264 shares.
Aethlon Medical, a pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that the Company's Chairman and Chief Executive Officer, Jim Joyce, will present at The Wall Street Analyst Forum 25th Annual Institutional Investor Conference on Thursday, June 19th, at 12:05 PM EDT. Mr. Joyce's presentation will include an update on a forthcoming FDA-cleared study of the Aethlon Hemopurifier(r), a review of the Company's cancer programs, and a progress report on Exosome Sciences, Inc., a diagnostic subsidiary recently launched by the Company.
Aethlon Medical creates innovative medical devices to address life-threatening diseases. The Aethlon ADAPT(tm) (Adaptive Dialysis-like Affinity Platform Technology) establishes the basis for a new class of therapeutics that target the rapid elimination of disease enabling particles from the circulatory system of treated patients. The lead Aethlon ADAPT(tm) product is the Hemopurifier(r), a device that addresses a broad-spectrum of viral pathogens as well as tumor-secreted exosomes that suppress the immune system of cancer patients. Aethlon is also operating under two government contracts with the Defense Advanced Research Projects Agency (DARPA) related the development of a medical device to reduce the incidence of sepsis. Exosome Sciences, Inc. is a majority owned Aethlon subsidiary that is advancing exosome-based strategies to diagnose and monitor cancer and infectious disease progression.
AEMD closed the day at $.165, 13.16% lower than its previous close of $.19.
PennyPickAlerts.com is one of the most talked about stock newsletters in the world. To receive 100% FREE stock alerts that have incredible potential, sign up here:
Ekso Bionics Holdings' CEO To Present Corporate Update
Ekso Bionics Holdings, Inc. (OTCQB: EKSO) saw its share volume remain strong on June 18th with 129,739 shares exchanging hands, slightly higher than its three month daily average volume of 79,620 shares.
Just this morning, Ekso Bionics Holdings announced that Nathan Harding, chief executive officer and co-founder will present a corporate update at the 9th Annual JMP Securities Healthcare Conference on Tuesday, June 24, 2014 at 2:30 p.m. EDT in New York City. A live demonstration of their bionic exoskeleton technology will also be provided.
Ekso Bionics designs, develops, and commercializes exoskeletons, or wearable robots, which have a variety of applications in the medical, military, industrial, and consumer markets. Exoskeletons are ready-to-wear, battery-powered robots that are strapped over the user's clothing, enabling individuals to achieve mobility, strength, and endurance not otherwise possible. Ekso Bionics' lead product, EksoTM, is a wearable bionic suit that enables individuals with any amount of lower extremity weakness to stand up and walk over ground. Ekso is forging a new frontier in rehabilitation for people living with the consequences of stroke, spinal cord injury and other neurological conditions affecting gait.
EKSO closed the day at $2.18, 3.95% lower than its previous close of $2.28.
Cynk Technology Corp. Sees Rise In Share Volume
Cynk Technology Corp. (OTCPINK: CYNK) saw its share volume soar on June 18th with 192,534 shares exchanging hands, seven times higher than its three month daily average volume of 26,531 shares.
With no recent news, nor any major operations, one can only speculate why this uptick in volume occurred, but here is what is known about the company:
Cynk Technology Corp., a development stage company, focuses on operating a social network. Its social network is based on showing the types of people the user is connected with and associated. The company intends to serve seekers, who want to meet people; mavens, who know a lot of people; and targets, who are people that other people want to meet. The company was formerly known as Introbuzz, Inc. and changed its name to Cynk Technology Corp. in July 2013.
CYNK closed the day at $2.10, 6.67% lower than its previous close of $2.25.
Pennypickalerts.com issues momentum alerts on stocks that can provide gains to day traders.
Pennypickalerts.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more.
Pennypickalerts.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals Pennypickalerts.com is often in the know of several large investor awareness campaigns being deployed.
Timing is everything when trading Penny Stocks. Gain an Edge by joining the Pennypickalerts.com newsletter and receiving alerts from a Pro-Active team of researchers. Pennypickalerts.com believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.pennypickalerts.com
Pennypickalerts.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always own due diligence with any potential investment.